Targeting the Growth Factors and Angiogenesis Pathways: Small Molecules in Solid Tumors
Targeting the Growth Factors and Angiogenesis Pathways: Small Molecules in Solid Tumors
复制标题
DOI：
10.1002/jso.21776
复制
发表时间：
2011-05-01
影响因子：
2.5
通讯作者：
Wanebo, Harold
中科院分区：
文献类型：
--
作者：
Berz, David;Wanebo, Harold
过去几十年的研究使我们对实体瘤的生物学有了更好的了解。在一些实体瘤恶性肿瘤中，已经确定了导致恶性转化的单分子事件，而在其他恶性肿瘤中，多种途径似乎同时发挥作用。对这些途径的描绘导致了治疗靶点的确定。现在有多种化合物可以治疗这些分子畸变。随着新型生物疗法的广泛使用，人们对预测临床反应的生物特征的理解也更加广泛。本综述重点关注小分子酪氨酸激酶抑制剂对胃肠道间质瘤以及肝细胞癌、非小细胞肺癌、肾细胞癌和乳腺癌的临床治疗，将一些临床进展与实体瘤恶性肿瘤的单克隆抗体疗法相结合。它强调了预测生物疗法疗效的相关生物标志物的最新进展，并详细阐述了它们在实体瘤恶性肿瘤患者临床管理中的相关性。 J.外科医生。安科尔。 2011；103：574-586。 (C) 2011 Wiley-Liss, Inc.
Research over the last decades has provided us with a better understanding of the biology of solid tumors. In some solid tumor malignancies single molecular events leading to malignant transformation have been identified, whilst in others multiple pathways seem to play a role simultaneously. The delineation of such pathways has led to the identification of therapeutic targets. Multiple compounds are available now to treat those molecular aberrations. With the wider use of newer biologic therapies, the understanding of biologic characteristics predicting a clinical response has broadened. This review focuses on the clinical management of gastrointestinal stromal tumors as well as hepatocellular, non small cell lung, renal cell and breast cancer with small molecule tyrosine kinase inhibitors, integrating some of the clinical advances with monoclonal antibody therapies in solid tumor malignancies. It highlights recent advances in relevant biomarkers to predict efficacy of biologic therapies and elaborates on their relevance in the clinical management of patients with solid tumor malignancies. J. Surg. Oncol. 2011;103:574-586. (C) 2011 Wiley-Liss, Inc.